Darbepoetin alfa biosimilar - Hetero Drugs

Drug Profile

Darbepoetin alfa biosimilar - Hetero Drugs

Alternative Names: Actorise

Latest Information Update: 02 Sep 2016

Price : $50

At a glance

  • Originator Hetero Drugs
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 16 Aug 2016 Hetero Drugs plans a phase I trial in Healthy volunteers in India (SC and IV) (CTRI2016-03-006727)
  • 15 Mar 2016 Biomarkers information updated
  • 19 Jun 2014 Hetero Drugs & Cipla agree to co-promote darbepoetin alfa biosimilar in India for Anaemia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top